An open label, single center, healthy volunteers, phase 1 study assessing whether steady-state eluxadoline increases systemic exposure of the cytochrome P450 (CYP) 3A4 substrate midazolam
Latest Information Update: 14 Nov 2022
At a glance
- Drugs Eluxadoline (Primary) ; Midazolam (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacokinetics
Most Recent Events
- 14 Nov 2022 New trial record
- 01 Nov 2022 Results published in the Clinical Pharmacology in Drug Development